美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

亞盛醫藥

17.38

0.0000

成交量：- -

成交額：3,817.09萬

市值：14.94億

市盈率：- -

高：17.38

開：17.38

低：17.38

收：17.38

52周最高：18.00

52周最低：16.50

股本：8,598.86萬

流通股本：732.50萬

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

【券商聚焦】東吳證券維持亞盛醫藥(06855)「買入」評級指海外市場潛力較大預計收入將快速增長

亞盛醫藥下跌2.18%，報17.001美元/股

方正證券：維持亞盛醫藥-B(06855)「強烈推薦」評級公司赴美上市進一步打通美國孖展渠道

亞盛醫藥-B(06855)根據承銷協議發行2930萬股

智通财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/AAPGV"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AAPGV","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPGV\",,,,,undefined,":{"symbol":"AAPGV","market":"US","secType":"STK","nameCN":"亞盛醫藥","latestPrice":17.38,"timestamp":1737752400000,"preClose":17.38,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":7325000,"shares":85988600,"eps":0,"marketStatus":"已收盤","change":0,"latestTime":"01-24 16:00:00 EST","open":17.38,"high":17.38,"low":17.38,"amount":38170939.23419999,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1770800400000},"marketStatusCode":5,"symbolChange":{"newSymbol":"AAPG","executeDate":"2025-01-27"},"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":17.38,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AAPGV\",,,,,undefined,":{"symbol":"AAPGV","floatShares":7325000,"roa":"--","roe":"--","lyrEps":0,"shares":85988600,"dividePrice":0,"high":17.38,"amplitude":0,"preClose":17.38,"low":17.38,"week52Low":16.5,"pbRate":"--","week52High":18,"institutionHeld":0,"latestPrice":17.38,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":17.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AAPGV\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-01-27","symbol":"AAPGV","oldSymbol":"AAPGV","defaultRemindTime":1737988200000,"newSymbol":"AAPG","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1737954000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AAPGV\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AAPGV\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AAPGV\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2506559657","title":"【券商聚焦】東吳證券維持亞盛醫藥(06855)「買入」評級 指海外市場潛力較大 預計收入將快速增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2506559657","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506559657?lang=zh_tw&edition=fundamental","pubTime":"2025-01-28 10:34","pubTimestamp":1738031679,"startTime":"0","endTime":"0","summary":"其中，耐立克已在国内获批上市，海外权益授权武田，开启重磅全球合作。此外，耐立克已获FDA批准在美国开展III期注册临床，预计25年完成患者入组，26年在美国递交上市申请。APG-115是首个在国内进入临床阶段的MDM2-p53抑制剂，联合用药潜力较大。考虑公司收入增长较快，海外市场潜力较大，维持“买入”评级。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1952309","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855","601555","AAPGV","AAPG"],"gpt_icon":0},{"id":"2506302192","title":"亞盛醫藥下跌2.18%，報17.001美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2506302192","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506302192?lang=zh_tw&edition=fundamental","pubTime":"2025-01-28 00:41","pubTimestamp":1737996097,"startTime":"0","endTime":"0","summary":"1月28日，亚盛医药(AAPG)盘中下跌2.18%，截至00:41，报17.001美元/股，成交130.83万美元。财务数据显示，截至2024年06月30日，亚盛医药收入总额8.24亿人民币，同比增长477.25%；归母净利润1.63亿人民币，同比增长140.51%。大事提醒：1月24日，亚盛医药于2025-01-24调整为1ADS等于4普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/01/28004147864327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["AAPG","AAPGV"],"gpt_icon":0},{"id":"2506315428","title":"方正證券：維持亞盛醫藥-B(06855)「強烈推薦」評級 公司赴美上市進一步打通美國孖展渠道","url":"https://stock-news.laohu8.com/highlight/detail?id=2506315428","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506315428?lang=zh_tw&edition=fundamental","pubTime":"2025-01-27 09:47","pubTimestamp":1737942469,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，方正证券发布研报称，1月24日，亚盛医药-B成功登录纳斯达克上市，此次公司登录美股募资约1.26亿美元，进一步打通了美国融资渠道，获得了新的资金支持，为后续产品发展提供了更多资源和确定性，有望加速奥雷巴替尼的全球商业化进展以及其他管线的研发进度。方正证券主要观点如下：事件：亚盛医药于2025年1月24日在美国纳斯达克正式上市，股票代码为AAPG。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1244357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601901","AAPG","06855","AAPGV"],"gpt_icon":0},{"id":"2506368310","title":"亞盛醫藥-B(06855)根據承銷協議發行2930萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2506368310","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506368310?lang=zh_tw&edition=fundamental","pubTime":"2025-01-27 08:03","pubTimestamp":1737936189,"startTime":"0","endTime":"0","summary":"亚盛医药-B(06855)发布公告，于2025年1月24日根据2025年1月23日...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_31.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_31.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1244311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["AAPG","06855","BK1574","AAPGV","BK1161"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AAPGV\",params:#limit:6,delay:false,,,undefined,":[]}}